67.67 0.00 (0.00%)
After hours: 4:56PM EST
|Bid||65.01 x 800|
|Ask||69.57 x 1200|
|Day's Range||66.65 - 68.60|
|52 Week Range||58.33 - 102.63|
|Beta (3Y Monthly)||1.71|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 13, 2019 - Feb 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||83.67|
Roche (RHHBY) signs collaboration agreement with Merck for developing a companion diagnostic test to identify patients for treatment with the latter's Keytruda.
Shire's (SHPG) pending acquisition by Takeda Pharmaceuticals for $62 billion gets approval from shareholders of both the companies.
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / U.S. markets closed up on Monday as the U.S. and China came to an agreement of a 90-day trade war truce at the G-20 meeting in Argentina. The Dow Jones Industrial ...
Incyte Corporation (INCY) announces updated results from its pivotal Phase 2 REACH1 study evaluating ruxolitinib (Jakafi®) in combination with corticosteroids as a treatment for patients with acute graft-versus-host disease (GVHD) who have had an inadequate response to corticosteroids. As previously announced, the study met its primary endpoint, demonstrating an overall response rate (ORR) of 55 percent (n=39/71) at Day 28, along with a best overall response rate (BORR) – patients achieving a response at any time point during the study – of 73 percent (n=52/71).
Large-cap pharma stocks are seeing some upward momentum and are on track to finish the year with handsome gains. As the year draws to a close, it remains to be seen if these stocks can sustain the ongoing ...
Incyte (INCY) today announced the appointment of Dashyant Dhanak, Ph.D. as Executive Vice President and Chief Scientific Officer, effective December 10, 2018. Dr. Dhanak will succeed Dr. Reid Huber, who has been at Incyte since 2002 and is leaving the Company to pursue opportunities in the early-stage life sciences community. “Reid’s contributions to Incyte have been instrumental in its evolution from a start-up operation to the world-class discovery engine of today, and I thank him most sincerely for his commitment and critical thinking over the last 16 years,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
I am going to run you through how I calculated the intrinsic value of Incyte Corporation (NASDAQ:INCY) by projecting its future cash flows and then discounting them to today’s value. Read More...
Investors may know Eli Lilly for its diabetes treatments. But analysts say the Big Pharma giant is bound to get a boost from its migraine prevention and immunology drugs.
AstraZeneca (AZN) announced that Imfinzi as a monotherapy or in combination with tremelimumab failed to improve overall survival in first-line NSCLC. The combination had also failed to improve progression free survival last year.
Merck's (MRK) Keytruda meets primary endpoint of overall survival in a phase III study evaluating it for the second-line treatment of advanced esophageal cancer.
Incyte Corporation announced today that it will present at Evercore ISI HEALTHCONx on Wednesday, November 28, 2018 at 3:30 pm EST in Boston.
Exelixis (EXEL) reported net income of $126.6 million in the third quarter compared to $81.4 million in the third quarter of 2017. The company’s net income over the first nine months of this year amounted to $330.0 million compared to $115.7 million in the same period the prior year.
NEW YORK, Nov. 05, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.